These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 219469)

  • 41. Angiotensin-converting enzyme inhibition: a new medical therapy for hypertension?
    Favre L; Hollifield JW; McKinstry DN
    J Tenn Med Assoc; 1978 Mar; 71(3):201-2. PubMed ID: 207928
    [No Abstract]   [Full Text] [Related]  

  • 42. [Synthesis of angiotensin-converting enzyme inhibitors and its application to experimental hypertensive rat for understanding the pathogenesis of renovascular hypertension (author's transl)].
    Mikami H; Ogihara T; Nakamura M; Hata T; Mandai T; Kumahara Y
    Nihon Jinzo Gakkai Shi; 1978 Jul; 20(7):827-33. PubMed ID: 214597
    [No Abstract]   [Full Text] [Related]  

  • 43. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension.
    Weinberger MH
    Hypertension; 1983; 5(5 Pt 2):III132-8. PubMed ID: 6313523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.
    Vaughan ED; Carey RM; Ayers CR; Peach MJ
    J Clin Endocrinol Metab; 1979 May; 48(5):869-71. PubMed ID: 219011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Captopril (SQ 14,225) (D-3-mercapto-2-methylpropranoyl-L-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent.
    Rubin B; Antonaccio MJ; Horovitz ZP
    Prog Cardiovasc Dis; 1978; 21(3):183-94. PubMed ID: 214818
    [No Abstract]   [Full Text] [Related]  

  • 46. [Comparison of blood pressure responses to captopril, an orally active converting enzyme inhibitor, in rats with various forms of experimental hypertension (author's transl)].
    Mikami H; Ogihara T; Kanda T; Higaki J; Naka T; Maruyama A; Hata T; Iwanaga K; Kumahara Y
    Nihon Naibunpi Gakkai Zasshi; 1980 Feb; 56(2):180-96. PubMed ID: 6245943
    [No Abstract]   [Full Text] [Related]  

  • 47. Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients.
    Cody RJ; Tarazi RC; Bravo EL; Fouad FM
    Clin Sci Mol Med; 1978 Nov; 55(5):453-9. PubMed ID: 214268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiotensin converting enzyme inhibition in renovascular hypertension: failure of the stenotic kidney.
    Schalekamp MA; Wenting GJ
    Lancet; 1984 Feb; 1(8374):464. PubMed ID: 6142203
    [No Abstract]   [Full Text] [Related]  

  • 49. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.
    Lopez-Ovejero JA; Saal SD; D'Angelo WA; Cheigh JS; Stenzel KH; Laragh JH
    N Engl J Med; 1979 Jun; 300(25):1417-9. PubMed ID: 220537
    [No Abstract]   [Full Text] [Related]  

  • 50. Angiotensin converting-enzyme inhibitor in refractory hypertension.
    Koch-Weser J
    N Engl J Med; 1978 Aug; 299(7):363-4. PubMed ID: 210382
    [No Abstract]   [Full Text] [Related]  

  • 51. A specific orally active inhibitor of angiotensin-converting enzyme in man.
    Ferguson RK; Turini GA; Brunner HR; Gavras H; McKinstry DN
    Lancet; 1977 Apr; 1(8015):775-8. PubMed ID: 66571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiotensin converting enzyme inhibitors as antihypertensive agents: 1-[(2-mercaptocycloalkyl)carbonyl]-L-prolines.
    Ciabatti R; Padova G; Bellasio E; Tarzia G; Depaoli A; Battaglia F; Cellentani M; Barone D; Baldoli E
    J Med Chem; 1986 Mar; 29(3):411-7. PubMed ID: 3005576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Captopril effect on hypertension in patient with renin-producing tumour.
    Aurell M; Rudin A; Tisell LE; Kindblom LG; Sandberg G
    Lancet; 1979 Jul; 2(8134):149-50. PubMed ID: 88582
    [No Abstract]   [Full Text] [Related]  

  • 54. Response of mineralocorticoid hypertensive animals to an angiotensin I converting enzyme inhibitor.
    Douglas BH; Langford HG; McCaa RE
    Proc Soc Exp Biol Med; 1979 May; 161(1):86-7. PubMed ID: 220620
    [No Abstract]   [Full Text] [Related]  

  • 55. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.
    Ondetti MA; Rubin B; Cushman DW
    Science; 1977 Apr; 196(4288):441-4. PubMed ID: 191908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Renovascular hypertension. Stents are in great demand despite the scantiness of relevant data].
    Aumiller J
    MMW Fortschr Med; 2007 Mar; 149(11):43-4. PubMed ID: 20104701
    [No Abstract]   [Full Text] [Related]  

  • 57. [Captopril and acute renovascular hypertension. A case report].
    Soubihe NV; Ambrósio CA; Ciconelli AJ; Contrera JD
    Arq Bras Cardiol; 1984 Jun; 42(6):415-7. PubMed ID: 6393920
    [No Abstract]   [Full Text] [Related]  

  • 58. Acute vasodepressor effect of D-3-mercapto-2-methylpropanoyl-L-proline (SQ 14,225) in the stroke-prone substrain of spontaneously hypertensive rats (SHRSP).
    Watanabe TX; Sokabe H
    Jpn J Pharmacol; 1979 Feb; 29(1):133-5. PubMed ID: 222924
    [No Abstract]   [Full Text] [Related]  

  • 59. Antihypertensive agents: angiotensin converting enzyme inhibitors. 1-[3-(Acylthio)-3-aroylpropionyl]-L-prolines.
    McEvoy FJ; Lai FM; Albright JD
    J Med Chem; 1983 Mar; 26(3):381-93. PubMed ID: 6298428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nifedipine as a substitute for converting enzyme inhibitors in the treatment of renovascular hypertension.
    Bursztyn M; Grossman E; Rosenthal T
    Clin Exp Hypertens A; 1985; 7(8):1187-97. PubMed ID: 2994918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.